Octagon Capital Advisors LP 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Octagon Capital Advisors LP disclosed 34 US equity positions worth $508.2m in its Q1 2025 13F filing. The largest position was NUVATION BIO INC at 9.5% of the reported book, followed by APLSUSD and DNTH. Against the Q4 2024 filing, it opened 8 new positions, added to 4 and reduced 9 among the top 34 holdings.
What did Octagon Capital Advisors LP own in Q1 2025? Top 34 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | NUVATION BIO INC | 9.5% | $48.1m | 27,330,800 | 8650% | added | |
| 2 | APLSUSD APELLIS PHARMACEUTICALS INC | 9.0% | $45.8m | 2,094,000 | -30% | reduced | |
| 3 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 8.4% | $42.5m | 2,341,667 | 11% | added |
| 4 | AVBP ARRIVENT BIOPHARMA INC | 7.5% | $38.1m | 2,059,387 | 0% | held | |
| 5 | TRVI TREVI THERAPEUTICS INC | Healthcare | 4.1% | $20.9m | 3,322,000 | – | new |
| 6 | CNTA CENTESSA PHARMACEUTICALS PLC | 4.0% | $20.5m | 1,425,000 | -29% | reduced | |
| 7 | GOSS GOSSAMER BIO INC | Healthcare | 4.0% | $20.2m | 18,350,000 | 0% | held |
| 8 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.5% | $17.8m | 2,425,000 | 0% | held |
| 9 | BRD1EUR MIND MEDICINE MINDMED INC | 3.5% | $17.7m | 3,018,000 | 0% | held | |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.3% | $16.6m | 2,763,000 | 0% | held |
| 11 | 4XC1 KALVISTA PHARMACEUTICALS INC | 3.1% | $15.8m | 1,370,000 | 0% | held | |
| 12 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 2.9% | $14.9m | 10,700,000 | 2% | added |
| 13 | NUVB NUVATION BIO INC | Healthcare | 2.7% | $13.9m | 7,900,000 | -14% | reduced |
| 14 | VRNA VERONA PHARMA PLC | 2.7% | $13.8m | 217,264 | -62% | reduced | |
| 15 | TRML TOURMALINE BIO INC | 2.7% | $13.8m | 905,000 | – | new | |
| 16 | MERUS N V | 2.6% | $13.0m | 308,000 | 0% | held | |
| 17 | PHVS PHARVARIS N V | 2.4% | $12.1m | 769,815 | -1% | reduced | |
| 18 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.3% | $11.6m | 296,000 | – | new |
| 19 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.2% | $11.1m | 904,000 | 0% | held |
| 20 | ATYR ATYR PHARMA INC | Healthcare | 2.1% | $10.7m | 3,552,000 | 295% | added |
| 21 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 2.1% | $10.6m | 329,000 | -33% | reduced |
| 22 | VSTM VERASTEM INC | Healthcare | 2.0% | $10.4m | 1,720,000 | – | new |
| 23 | RGLS REGULUS THERAPEUTICS INC | 1.6% | $8.1m | 4,637,076 | -4% | reduced | |
| 24 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 1.5% | $7.9m | 625,000 | – | new |
| 25 | ABVX ABIVAX SA | 1.5% | $7.7m | 1,230,000 | – | new | |
| 26 | ERAS ERASCA INC | Healthcare | 1.4% | $7.0m | 5,136,795 | 0% | held |
| 27 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.2% | $6.1m | 450,000 | -48% | reduced |
| 28 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.2% | $5.9m | 1,115,000 | 0% | held |
| 29 | UNCY UNICYCIVE THERAPEUTICS INC | 1.1% | $5.7m | 10,000,000 | 0% | held | |
| 30 | MAZE MAZE THERAPEUTICS INC | 1.0% | $5.2m | 468,000 | – | new | |
| 31 | CATX PERSPECTIVE THERAPEUTICS INC | 0.9% | $4.8m | 2,250,000 | -2% | reduced | |
| 32 | KLRS KALARIS THERAPEUTICS INC | 0.8% | $3.9m | 481,000 | – | new | |
| 33 | NGNE NEUROGENE INC | 0.7% | $3.5m | 303,000 | 0% | held | |
| 34 | HELIX ACQUISITION CORP II | 0.6% | $2.8m | 250,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.